Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Parkinson’s Disease cannabidiol:

Search results

Items: 1 to 20 of 51

1.

Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson's disease.

de Faria SM, de Morais Fabrício D, Tumas V, Castro PC, Ponti MA, Hallak JE, Zuardi AW, Crippa JAS, Chagas MHN.

J Psychopharmacol. 2020 Jan 7:269881119895536. doi: 10.1177/0269881119895536. [Epub ahead of print]

PMID:
31909680
2.

Medicinal and Synthetic Cannabinoids for Pediatric Patients: A Review of Clinical Effectiveness and Guidelines [Internet].

Chao YS, McCormack S.

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Oct 11.

3.

Cannabis and Neuropsychiatric Disorders: An Updated Review.

Chayasirisobhon S.

Acta Neurol Taiwan. 2019 Jun 15;28(2):27-39. Review.

PMID:
31867704
4.

Cannabinoids and the expanded endocannabinoid system in neurological disorders.

Cristino L, Bisogno T, Di Marzo V.

Nat Rev Neurol. 2020 Jan;16(1):9-29. doi: 10.1038/s41582-019-0284-z. Epub 2019 Dec 12. Review.

PMID:
31831863
5.

Cannabis and cannabinoids.

[No authors listed]

Med Lett Drugs Ther. 2019 Nov 18;61(1585):179-182. Review. No abstract available.

PMID:
31770357
6.

Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease.

Crivelaro do Nascimento G, Ferrari DP, Guimaraes FS, Del Bel EA, Bortolanza M, Ferreira-Junior NC.

Neuropharmacology. 2020 Feb;163:107808. doi: 10.1016/j.neuropharm.2019.107808. Epub 2019 Nov 7.

PMID:
31706993
7.

Cannabidiol partially blocks the sleepiness in hypocretin-deficient rats. Preliminary data.

Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Morales-Lara D, Mechoulam R, Drucker-Colín R.

CNS Neurol Disord Drug Targets. 2019 Oct 21. doi: 10.2174/1871527318666191021143300. [Epub ahead of print]

PMID:
31642794
8.

Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.

Junior NCF, Dos-Santos-Pereira M, Guimarães FS, Del Bel E.

Neurotox Res. 2020 Jan;37(1):12-29. doi: 10.1007/s12640-019-00109-8. Epub 2019 Oct 22. Review.

PMID:
31637586
9.

Effects of cannabidiol (CBD) in neuropsychiatric disorders: A review of pre-clinical and clinical findings.

Elsaid S, Kloiber S, Le Foll B.

Prog Mol Biol Transl Sci. 2019;167:25-75. doi: 10.1016/bs.pmbts.2019.06.005. Epub 2019 Aug 28.

PMID:
31601406
10.

Biological bases for a possible effect of cannabidiol in Parkinson's disease.

Ferreira-Junior NC, Campos AC, Guimarães FS, Del-Bel E, Zimmermann PMDR, Brum Junior L, Hallak JE, Crippa JA, Zuardi AW.

Braz J Psychiatry. 2019 Jul 15. pii: S1516-44462019005012104. doi: 10.1590/1516-4446-2019-0460. [Epub ahead of print]

11.

Cannabidiol: a hope to treat non-motor symptoms of Parkinson's disease patients.

Saleem S, Anwar A.

Eur Arch Psychiatry Clin Neurosci. 2019 Jun 5. doi: 10.1007/s00406-019-01023-y. [Epub ahead of print] No abstract available.

PMID:
31168642
12.

Cannabidiol: The Need for More Information About Its Potential Benefits and Side Effects.

Hande K.

Clin J Oncol Nurs. 2019 Apr 1;23(2):131-134. doi: 10.1188/19.CJON.131-134.

PMID:
30880812
13.

Is cannabidiol the ideal drug to treat non-motor Parkinson's disease symptoms?

Crippa JAS, Hallak JEC, Zuardi AW, Guimarães FS, Tumas V, Dos Santos RG.

Eur Arch Psychiatry Clin Neurosci. 2019 Feb;269(1):121-133. doi: 10.1007/s00406-019-00982-6. Epub 2019 Jan 31. Review.

PMID:
30706171
14.

Cannabis Therapeutics and the Future of Neurology.

Russo EB.

Front Integr Neurosci. 2018 Oct 18;12:51. doi: 10.3389/fnint.2018.00051. eCollection 2018.

15.

Medical Use of Cannabinoids.

Fraguas-Sánchez AI, Torres-Suárez AI.

Drugs. 2018 Nov;78(16):1665-1703. doi: 10.1007/s40265-018-0996-1. Review.

PMID:
30374797
16.

Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.

Crippa JA, Guimarães FS, Campos AC, Zuardi AW.

Front Immunol. 2018 Sep 21;9:2009. doi: 10.3389/fimmu.2018.02009. eCollection 2018. Review.

17.

Cannabidiol enhances morphine antinociception, diminishes NMDA-mediated seizures and reduces stroke damage via the sigma 1 receptor.

Rodríguez-Muñoz M, Onetti Y, Cortés-Montero E, Garzón J, Sánchez-Blázquez P.

Mol Brain. 2018 Sep 17;11(1):51. doi: 10.1186/s13041-018-0395-2.

18.

A Brief Background on Cannabis: From Plant to Medical Indications.

Klumpers LE, Thacker DL.

J AOAC Int. 2019 Mar 1;102(2):412-420. doi: 10.5740/jaoacint.18-0208. Epub 2018 Aug 23. Review.

PMID:
30139415
19.

Evidence for the use of "medical marijuana" in psychiatric and neurologic disorders.

Noel C.

Ment Health Clin. 2018 Mar 23;7(1):29-38. doi: 10.9740/mhc.2017.01.029. eCollection 2017 Jan.

20.

GPR3, GPR6, and GPR12 as novel molecular targets: their biological functions and interaction with cannabidiol.

Laun AS, Shrader SH, Brown KJ, Song ZH.

Acta Pharmacol Sin. 2019 Mar;40(3):300-308. doi: 10.1038/s41401-018-0031-9. Epub 2018 Jun 25. Review.

PMID:
29941868

Supplemental Content

Loading ...
Support Center